81
57
Growth Score
-10 pts
Heat Score
-23 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
249472
Proxygen is a biotechnology firm specializing in protein degradation therapy for treatment of cancer and other life threatening dieseses.
- Chiara Conti: Chief Scientific OfficerPast Role: Blueprint Medicines, Senior Director
About the Company
Proxygen is reshaping the druggable space. Their company harnesses technology and know-how to exploit this potential, thereby redefining the borders of the druggable target space. They developed rational discovery assays that, for the first time, enabled the identification and development of novel glue degraders at scale, putting them at the
forefront of charting this unexplored chemical space.
